BioPharma Dive July 17, 2024
Sales of J&J’s depression treatment are on pace to eclipse $1 billion this year, which one Wall Street analyst sees as evidence that psychedelics like it can be commercially viable.
Dive Brief:
- Sales of Johnson & Johnson’s depression drug Spravato accelerated in the second quarter, putting the medicine on pace to eclipse $1 billion in annual revenue this year.
- Globally, Spravato sales totaled $271 billion between April and June, a 61% increase from the same period one year before and a 20% jump from the first quarter. The numbers, disclosed by J&J alongside second quarter earnings Wednesday, reflected “increased physician and patient confidence,” Jessica Moore, the company’s head of investor relations, said on a conference call.
- Approved for treatment-resistant...
Today's Sponsors
Today's Sponsor